

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				ATTY. DOCKET NO. LIT-PI-529D1		SERIAL NO. <i>1618560</i> Filed Herewith	
LIST OF ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT William K. Keener			
				FILING DATE Filed Herewith		GROUP <i>Unknown</i> 1648	
U.S. PATENT DOCUMENTS							
*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
<i>JK</i>	AA	5591829	01/07/97	Matsushita	530	391.1	
	AB	5633388	05/27/97	Diana et al	514	393	
	AC	5645836	07/08/97	Kitto	424	159.1	
	AD	5677274	10/14/97	Leppia et al	514	2	
	AE	5684024	11/04/97	Diana et al	548	365.4	
	AF	5767072	06/16/98	Vitetta et al	424	194.1	
	AG	5821243	10/13/98	Diana et al	544	238	
	AH	5830894	11/03/98	Pevear et al	514	243	
	AI	5834599	11/10/98	Chang et al	530	388.35	
	AJ	5935957	8/10/99	Diana et al	514	247	
	AK	6333303	12/25/01	Borgford	514	2	
FOREIGN PATENT DOCUMENTS							
		Document Number	Date	Country	Class	Subclass	Translation
							Yes No
<i>JK</i>	AL	WO97/41233	11/6/97	PCT			
	AM						
	AN						
	AO						
	AP						
OTHER REFERENCES (including Author, Title, Date, Pertinent Pages, Etc.)							
<i>JK</i>	AR		Lord, J.M., et al. "Ricin: Structure, Mode of Action, and Some Current Applications". <u>The FASEB Journal</u> , Vol.8 pp. 201 and 206, 2/94.				
			Richardson, P.T., et al. "Recombinant Prorcin Binds Galactose But Does Not Depurinate 28 S Ribosomal RNA," <u>FEBS</u> 07564, Vol 255, No. 1, page 15, 9/89.				
	AS		Westby, M.W., et al. "Preparation and Characterization of Recombinant Prorcin Containing an Alternative Protease-Sensitive Linker Sequence," <u>Bioconjugate Chemistry</u> , 1992, 3, p. 375.				
			Darket, P.L., et al. "Human Immunodeficiency Virus Protease," <u>Journal of Biological Chemistry</u> , Vol 264, No. 4, p. 2307 1989.				
	AT		Jordan, S.P., et al. "Activity and Dimerization of Human Immunodeficiency Virus Protease as a Function of Solvent Composition and Enzyme Concentration," <u>Journal of Biological Chemistry</u> , Vol. 267, No. 28, p. 20028. 1992.				
			Van Quen, M.G., "Rationale for the Use of Immunotoxins in the Treatment of HIV-Infected Humans," <u>Journal of Drug Targeting</u> , Vol 5, No. 2 p. 75, 1997.				
EXAMINER <i>JK</i>			DATE CONSIDERED <i>3/16/05</i>				
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>							

Form PTO-1449			U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. LIT-PI-529		SERIAL NO. Filed Herewith	
LIST OF ART CITED BY APPLICANT (Use several sheets if necessary)			APPLICANT William K. Keener, et al					
			FILING DATE Filed Herewith		GROUP Unknown			
U.S. PATENT DOCUMENTS								
*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate	
	AA							
	AB							
	AC							
	AD							
	AE							
	AF							
	AG							
	AH							
	AI							
	AJ							
	AK							
FOREIGN PATENT DOCUMENTS								
		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	AL							
	AM							
	AN							
	AO							
	AP							
OTHER REFERENCES (including Author, Title, Date, Pertinent Pages, Etc.)								
<i>PS</i> <i>PS</i>	AR		Wachinger, M., et al, "Bryodin, a Single-Chain Ribosome-Inactivating Protein, Selectively Inhibits the Growth of HIV-1-Infected Cells and Reduces HIV-1 Production." <u>Research in Experimental Medicine</u> , 193:1-2, 1993.					
			Till, M.A., et al, "HIV-Infected Cells are Killed by rCF4-Ricin A Chain," <u>Science</u> , Vol. 24 p. 1166.					
	AS							
	AT							
EXAMINER			DATE CONSIDERED					
<i>JR</i>			3/16/05					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								